TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.


Options:
A: Arm Label: Daprodustat in ND participants; Type: EXPERIMENTAL; Interventions: Drug: 1 to 4 mg tablets of GSK1278863, Drug: 6 mg GSK1278863 tablet | Arm Label: Epoetin beta pegol in ND participants; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin beta pegol | Arm Label: Daprodustat in PD participants; Type: EXPERIMENTAL; Interventions: Drug: 1 to 4 mg tablets of GSK1278863, Drug: 6 mg GSK1278863 tablet | Intervention Type: DRUG; Name: 1 to 4 mg tablets of GSK1278863; Assigned to Arm(s): Daprodustat in ND participants, Daprodustat in PD participants | Intervention Type: DRUG; Name: 6 mg GSK1278863 tablet; Assigned to Arm(s): Daprodustat in ND participants, Daprodustat in PD participants | Intervention Type: DRUG; Name: Epoetin beta pegol; Assigned to Arm(s): Epoetin beta pegol in ND participants
B: Arm Label: BAY85-3934 (25mg OD); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: BAY85-3934 (50mg OD); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: BAY85-3934 (75mg OD); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: BAY85-3934 (25mg BID); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: BAY85-3934 (50mg BID); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAY85-3934; Assigned to Arm(s): BAY85-3934 (25mg BID), BAY85-3934 (25mg OD), BAY85-3934 (50mg BID), BAY85-3934 (50mg OD), BAY85-3934 (75mg OD) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BAY85-3934 (25mg BID), BAY85-3934 (25mg OD), BAY85-3934 (50mg BID), BAY85-3934 (50mg OD), BAY85-3934 (75mg OD), Placebo BID
C: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Alfa | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Different Dosages Oral Vitamin D on Serum Interleukin-6 in Preterm Infants With Late-onset Sepsis
Brief Summary: This is a randomized controlled trial (RCT) to evaluate the influence of different doses of vitamin D3 (800 IU/d versus 400 IU/d), on serum levels of interleukin (IL)-6, TNF-alpha and C- reactive (CRP) in premature infants with clinical evidence of late-onset sepsis and to assess its influence on clinical outcomes of these infants.


Options:
A: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A, Group B, Group C, Group D
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Calcium plus vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Calcium plus vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium plus vitamin D; Assigned to Arm(s): Calcium plus vitamin D
C: Arm Label: High-dose vitamin D; Type: EXPERIMENTAL; Interventions: Drug: High-dose vitamin D 3 | Arm Label: Conventional-dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional-Dose Vitamin D 3 | Intervention Type: DRUG; Name: High-dose vitamin D 3; Assigned to Arm(s): High-dose vitamin D | Intervention Type: DRUG; Name: Conventional-Dose Vitamin D 3; Assigned to Arm(s): Conventional-dose vitamin D
D: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Different Dosages Oral Vitamin D on Serum Interleukin-6 in Preterm Infants With Late-onset Sepsis
Brief Summary: This is a randomized controlled trial (RCT) to evaluate the influence of different doses of vitamin D3 (800 IU/d versus 400 IU/d), on serum levels of interleukin (IL)-6, TNF-alpha and C- reactive (CRP) in premature infants with clinical evidence of late-onset sepsis and to assess its influence on clinical outcomes of these infants.


Options:
A: Arm Label: High-dose vitamin D; Type: EXPERIMENTAL; Interventions: Drug: High-dose vitamin D 3 | Arm Label: Conventional-dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional-Dose Vitamin D 3 | Intervention Type: DRUG; Name: High-dose vitamin D 3; Assigned to Arm(s): High-dose vitamin D | Intervention Type: DRUG; Name: Conventional-Dose Vitamin D 3; Assigned to Arm(s): Conventional-dose vitamin D
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin D | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Atopic dermatitis patients: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral vitamin D | Arm Label: Atopic dermatitis patients: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral vitamin D; Assigned to Arm(s): Atopic dermatitis patients: Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Atopic dermatitis patients: Placebo
D: Arm Label: Sustained; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Diet-Limited; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Diet-Limited | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Sustained

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Health Through SkypeTM: Family-Based Intervention for Teens With Poorly Controlled Diabetes
Brief Summary: Compared family-based skills training (aka, Behavioral Family Systems Therapy) to youth with poorly controlled type 1 diabetes and their parents either face-to-face or over SkypeTM. Examined the differential impact on the youth's adherence to the diabetes medical regimen and the youth's blood sugar control.


Options:
A: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Supportive Non-Directive Therapy (SNDT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Non-directive Therapy (SNDT) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Supportive Non-directive Therapy (SNDT); Assigned to Arm(s): Supportive Non-Directive Therapy (SNDT)
B: Arm Label: Clinic; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BFST | Arm Label: Skype; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BFST | Intervention Type: BEHAVIORAL; Name: BFST; Assigned to Arm(s): Clinic, Skype
C: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A
D: Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): Cognitive Behavioral Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)
Brief Summary: This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once nightly at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). The novel pharmacokinetic profile of ADS-5102 is expected to achieve i) maximal concentrations in the early morning through mid-day, when LID can be troublesome, and ii) lower concentrations in the evening, potentially reducing the negative impact of amantadine on sleep. This pharmacokinetic profile could enable higher doses to be tolerated with a once-nightly ER formulation than can be tolerated with an immediate-release formulation. The once-nightly dosing regimen may also provide enhanced convenience and compliance.

In a previous clinical study, ADS-5102 met its primary endpoint; LID was significantly reduced as measured by the change in UDysRS score over 8 weeks vs. placebo.


Options:
A: Arm Label: APL-130277; Type: EXPERIMENTAL; Interventions: Drug: APL-130277 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: APL-130277; Assigned to Arm(s): APL-130277 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: control arm; Type: ACTIVE_COMPARATOR; Interventions: Other: control arm | Arm Label: virtual reality games arm; Type: EXPERIMENTAL; Interventions: Other: virtual reality games | Arm Label: robotic treadmill arm; Type: EXPERIMENTAL; Interventions: Other: robotic treadmill | Intervention Type: OTHER; Name: control arm; Assigned to Arm(s): control arm | Intervention Type: OTHER; Name: virtual reality games; Assigned to Arm(s): virtual reality games arm | Intervention Type: OTHER; Name: robotic treadmill; Assigned to Arm(s): robotic treadmill arm
C: Arm Label: ADS-5102 (amantadine HCl extended release); Type: EXPERIMENTAL; Interventions: Drug: ADS-5102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: ADS-5102; Assigned to Arm(s): ADS-5102 (amantadine HCl extended release) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Physical Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy; Assigned to Arm(s): Physical Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Individualized Comparative Effectiveness of Models Optimizing Patient Safety and Resident Education (iCOMPARE).
Brief Summary: The investigators are conducting a cluster randomized trial in a sample of 63 internal medicine (IM) training programs that are randomly assigned to either the current duty hour standards or less restricted flexible duty hour standards.

The trial includes a main protocol in which all randomized IM programs participate and two substudies. "Time and Motion" and "Sleep and Alertness", each conducted at a subset of IM programs and focusing on more detailed data collection at the intern level.

The main protocol will examine patient safety and costs as well as quality of education. The "Time and Motion" substudy examines additional educational outcomes. The "Sleep and Alertness" substudy examines intern sleep time and alertness.


Options:
A: Arm Label: Standard Duty Hour Schedule; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Flexible Duty Hour Schedule; Type: EXPERIMENTAL; Interventions: Behavioral: Flexible Duty Hour Schedule | Intervention Type: BEHAVIORAL; Name: Flexible Duty Hour Schedule; Assigned to Arm(s): Flexible Duty Hour Schedule
B: Arm Label: Intervention cohort; Type: EXPERIMENTAL; Interventions: Other: SCS intervention schedule | Arm Label: Control cohort; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SCS intervention schedule; Assigned to Arm(s): Intervention cohort
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: constant CPAP devices | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: automatic CPAP devices | Intervention Type: DEVICE; Name: constant CPAP devices; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: automatic CPAP devices; Assigned to Arm(s): 2
D: Arm Label: Provent; Type: ACTIVE_COMPARATOR; Interventions: Device: Provent® | Arm Label: Placebo-Provent; Type: PLACEBO_COMPARATOR; Interventions: Device: Provent®, Device: Placebo-Provent® | Arm Label: CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Provent®, Procedure: CPAP | Intervention Type: DEVICE; Name: Provent®; Assigned to Arm(s): CPAP, Placebo-Provent, Provent | Intervention Type: DEVICE; Name: Placebo-Provent®; Assigned to Arm(s): Placebo-Provent | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Economical Assessment of an Intervention to Reduce Potentially Inappropriate Medication in Polymedicated Elderly Patients
Brief Summary: Objective: To evaluate the clinical and economic impact of the application of an algorithm to improve the adequacy and safety of pharmacotherapy in elderly polymedicated (receiving 8 or more medications), not institutionalized.

Design: randomized, open, multicenter and two branches of parallel intervention clinical trial.

Intervention Study: primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient. Control intervention: usual procedure.

Main outcome measures: a) Discontinued medications, changed or changing doses, b) GP consultations, hospital emergency department and hospital admissions for acute illness, c) pharmaceutical expenditure, d) restart medication e) complications underlying diseases. Follow-up control at 1 month (security) and at 3, 6 and 12 months.


Options:
A: Arm Label: Motivational interview; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interview | Intervention Type: BEHAVIORAL; Name: Motivational interview; Assigned to Arm(s): Motivational interview
B: Arm Label: Audit + Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit + Feedback | Arm Label: Audit + Feedback + Educational Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Audit + Feedback, Behavioral: Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback; Assigned to Arm(s): Audit + Feedback, Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback + Educational Outreach; Assigned to Arm(s): Audit + Feedback + Educational Outreach
C: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: EHR Based Strategy to promote Safe and Appropriate Drug Use | Arm Label: Standard Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EHR Based Strategy to promote Safe and Appropriate Drug Use; Assigned to Arm(s): Intervention Arm
D: Arm Label: Pharmacist Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pharmacist Intervention; Assigned to Arm(s): Pharmacist Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Economical Assessment of an Intervention to Reduce Potentially Inappropriate Medication in Polymedicated Elderly Patients
Brief Summary: Objective: To evaluate the clinical and economic impact of the application of an algorithm to improve the adequacy and safety of pharmacotherapy in elderly polymedicated (receiving 8 or more medications), not institutionalized.

Design: randomized, open, multicenter and two branches of parallel intervention clinical trial.

Intervention Study: primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient. Control intervention: usual procedure.

Main outcome measures: a) Discontinued medications, changed or changing doses, b) GP consultations, hospital emergency department and hospital admissions for acute illness, c) pharmaceutical expenditure, d) restart medication e) complications underlying diseases. Follow-up control at 1 month (security) and at 3, 6 and 12 months.


Options:
A: Arm Label: Pharmacist Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pharmacist Intervention; Assigned to Arm(s): Pharmacist Intervention
B: Arm Label: Intervention; Type: OTHER; Interventions: Other: E-learning | Arm Label: Control; Type: OTHER; Interventions: Other: E-learning | Intervention Type: OTHER; Name: E-learning; Assigned to Arm(s): Control, Intervention
C: Arm Label: Multidisciplinary medication review; Type: EXPERIMENTAL; Interventions: Procedure: Multidisciplinary medication review | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Multidisciplinary medication review; Assigned to Arm(s): Multidisciplinary medication review
D: Arm Label: Multi-PAP intervention; Type: EXPERIMENTAL; Interventions: Other: Multi-PAP, Other: Usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Multi-PAP; Assigned to Arm(s): Multi-PAP intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Multi-PAP intervention, Usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Economical Assessment of an Intervention to Reduce Potentially Inappropriate Medication in Polymedicated Elderly Patients
Brief Summary: Objective: To evaluate the clinical and economic impact of the application of an algorithm to improve the adequacy and safety of pharmacotherapy in elderly polymedicated (receiving 8 or more medications), not institutionalized.

Design: randomized, open, multicenter and two branches of parallel intervention clinical trial.

Intervention Study: primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient. Control intervention: usual procedure.

Main outcome measures: a) Discontinued medications, changed or changing doses, b) GP consultations, hospital emergency department and hospital admissions for acute illness, c) pharmaceutical expenditure, d) restart medication e) complications underlying diseases. Follow-up control at 1 month (security) and at 3, 6 and 12 months.


Options:
A: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary collaboration structure | Intervention Type: OTHER; Name: Interdisciplinary collaboration structure; Assigned to Arm(s): Intervention
B: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Other: tele-expertise | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: tele-expertise; Assigned to Arm(s): experimental group
C: Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Other: Medicines optimisation | Intervention Type: OTHER; Name: Medicines optimisation; Assigned to Arm(s): Intervention arm
D: Arm Label: Pharmacist Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Pharmacist Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Pharmacist Intervention; Assigned to Arm(s): Pharmacist Intervention

Answer: D